Basic Search  |  Summaries  |  Advanced Search

Violation Tracker UK Individual Case

Company: Auden Mckenzie (Pharma Division) Ltd. and Accord-UK Ltd.
Current Parent Company: Intas Pharmaceuticals Ltd.
Parent at the Time of the Penalty Announcement: Intas Pharmaceuticals Ltd.
Recap of Ownership Changes: In 2015 Auden McKenzie was acquired by Actavis PLC, which sold its generics business in 2016 to Teva Pharmaceuticals, which sold its UK generics business to Accord Healthcare, a subsidiary of Intas Pharmaceuticals, in 2017.
Penalty: £2,882,238
Year: 2020
Date: 4 March, 2020
Offence Group: competition-related offences
Offence Type: price-fixing or anti-competitive practices
Violation Description: Auden Mckenzie and Accord-UK agreed to pay a £1,882,228 fine and make a payment of £1,000,000 to the NHS in settlement of a decision by the CMA that the companies had illegally colluded with King, another supplier of the drug nortriptyline, to fix prices and supply. King also paid a fine in settlement of the decision.
Action Type: agency action
Settlement Type: Settlement with the CMA
Case Number: 50507
Agency: Competition and Markets Authority
HQ Country of Parent: India
Ownership Structure of Parent: privately held
Major Industry of Parent: pharmaceuticals
Specific Industry of Parent: pharmaceuticals
Source of Data: (click here)